Ignite Creation Date:
2025-12-25 @ 4:02 AM
Ignite Modification Date:
2026-01-10 @ 1:10 AM
Study NCT ID:
NCT05970302
Status:
RECRUITING
Last Update Posted:
2023-08-01
First Post:
2023-07-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
NCC-009591
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None